Abstract
The human ATP binding cassette (ABC) family of transporter proteins plays an important role in the maintenance of homeostasis in vivo. The aim of this study is to evaluate the potential diagnostic, prognostic, and therapeutic value of the ABCA10 gene in BRCA. We found that ABCA10 expression was downregulated in different subgroups of breast cancer and strongly correlated with pathological stage in BRCA patients. Low expression of ABCA10 was associated with BRCA patients showing shorter overall survival (OS). ABCA10 expression may be regulated by promoter methylation, copy number variation (CNV) and kinase, and is associated with immune infiltration. Our study also demonstrated the potential role of ABCA10 modifications in tumor microenvironment (TME) cellular infiltration. Nevertheless, the regulatory mechanism remains unknown and immunotherapy is marginal in BRCA. We demonstrate the expression of different ABCA10 modulators in breast cancer associated with genetic variants, deletions, tumor mutation burden (TMB) and TME. Mutations in ABCA10 are positively associated with different immune cells in six different immune databases and play an important role in immune cell infiltration in breast cancer. Overall, this study provides evidence that ABCA10 could become the potential targets for precision treatment and new biomarkers in the prognosis of breast cancer.
Highlights
Breast cancer is one of the most common malignant tumors in women, with the highest incidence and mortality rate among all types of malignant tumors in women, posing a serious threat to women’s health [1].In recent years, the treatment of breast cancer has been developing, and various clinical treatments such as surgery, chemotherapy and targeted therapy have become more and more mature
After analysis through the ONCOMINE database, we found that ABCA10 levels were much lower than normal
The bar plot indicates the number of genetic mutations per patient, while the right bar plot displays the number of genetic mutations per gene. (B) The mRNA expression levels of ABCA10 in multiple cancers on ONCOMINE database
Summary
Breast cancer is one of the most common malignant tumors in women, with the highest incidence and mortality rate among all types of malignant tumors in women, posing a serious threat to women’s health [1].In recent years, the treatment of breast cancer has been developing, and various clinical treatments such as surgery, chemotherapy and targeted therapy have become more and more mature. Breast cancer is one of the most common malignant tumors in women, with the highest incidence and mortality rate among all types of malignant tumors in women, posing a serious threat to women’s health [1]. Due to the high heterogeneity and metastatic nature of breast cancer, there is still room for improvement in the www.aging-us.com mortality rate of breast cancer patients [2, 3]. It is important to select more effective drugs for breast cancer treatment, prolong the survival of patients and reduce the mortality rate of breast cancer. The typical structure of ABC transporter proteins consists of a pair of nucleotide-binding domains (NBDs) located on the cytoplasmic side of the membrane, where the NBDs function to bind and hydrolyze ATP to provide energy for substrate translocation and the transmembrane domains (TMDs) are involved in substrate recognition [5]. There are no reports of low expression and mutation of ABCA10 leading to the progression of breast cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
